Business Context and Reporting Period
This Form 8-K Current Report was filed by Akers Biosciences, Inc. (Ticker: AKER) on November 20, 2020. The report details corporate governance changes effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and does not contain financial performance data.
Material Changes
The primary material change reported is a restructuring of the Board of Directors and executive leadership roles:
- Joshua Silverman: Appointed as Chairman of the Board (previously a director).
- Christopher C. Schreiber: Resigned as Executive Chairman of the Board and was appointed as Chief Executive Officer (CEO), effective November 20, 2020. He continues to serve as President and principal executive officer.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, specific risk factors, or contingencies. Management commentary is limited to the confirmation that Mr. Schreiber's current employment agreement remains in effect.
Investor Verification Checklist
- Verify the updated composition of the Board of Directors on the company's investor relations website.
- Confirm the specific terms of the employment agreement for Christopher C. Schreiber in his new capacity as CEO.
- Review subsequent filings for any financial impact related to these leadership transitions.